Explore the latest developments concerning Pfizer Isn’t Dead.
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal
It’s becoming a familiar story: the Chinese drugs industry has signed another licensing deal with Big Pharma to fast track a weight-loss treatment.
This time the partners are a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH), which has developed an experimental anti-obesity pill, and the drugs giant Pfizer Inc. (PFE.US), which is looking to close the gap on its rivals in the booming weight management market.
Potentially worth more than $2 billion, the collaboration underscores how new medications developed in China are attracting multinational interest, especially the GLP-1 drugs that regulate blood sugar and help to control appetite.
HiBREW Coffee Maker Cafetera 20 Bar Inox Semi Automatic Super Slim ESE POD & Powder Espresso Machine Hot Water H11
The dynamic landscape of current events often brings forth significant discussions. Monitoring these developments provides crucial insights.
For more detailed information, explore updates concerning Pfizer Isn’t Dead.